INmune Bio (NASDAQ: INMB), a clinical-stage immunology
company focused on developing treatments that harness the patient’s innate
immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder
and CEO, and Mark Lowdell, Ph.D., Co-Founder and Chief Scientific Officer, will
be presenting at the first ever Targeting Innate Immunity Congress. Dr. Tesi and Dr.
Lowdell will also be instructing a course on the role of the tumor
microenvironment (“TME”) in immunosuppression at the event, which will take
place September 23rd – 25th in Cambridge, Massachusetts. INmune is set to use
this opportunity to showcase its two leading innate compounds to industry
leaders, experts, academic researchers and clinicians in the field of innate
immunity. In addition, Dr. Tesi will also take part in a speaking engagement in
Philadelphia at the second annual MarketsandMarkets Next Gen Immuno-Oncology Congress on
September 19th.
To view the full press release, visit http://ibn.fm/dSeP8
About INmune Bio, Inc.
INmune Bio, Inc. is a clinical-stage biotechnology company
developing therapies targeting the innate immune system to fight disease.
INmune Bio is developing three product platforms: two products that reengineer
the patient’s innate immune system’s response to cancer and one product to
treat neuroinflammation that is currently focused on Alzheimer’s disease.
INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s
NK cells to attack minimal residual disease, the remaining cancer cells that
are difficult to detect, which often cause relapse. INB03 inhibits
myeloid-derived suppressor cells (“MDSC”), which often cause resistance to
immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets
neuroinflammation, which causes microglial activation and neuronal cell death.
INmune Bio’s product platforms utilize a precision medicine approach for the
treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. For more information, visit the company’s website
at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
